| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 548190000 | Nitrogen attached directly to the thiazole ring by nonionic bonding | 15 |
| 548191000 | Plural nitrogens attached directly to the thiazole ring by nonionic bonding | 1 |
| 20090018341 | DAT1 - A synthetic diaminoketothiazole, its process of preparation and its use as a microtubule inhibitor, a probe for tubulin-microtubule system and a cytotoxic agent. Diaminoketothiazole of the formula (I) wherein Ar is 4-OMe-C | 01-15-2009 |
| 548193000 | Chalcogen attached indirectly to the thiazole ring by nonionic bonding | 13 |
| 20110218341 | CHEMICAL COMPOUNDS - The use of a compound of formula I | 09-08-2011 |
| 20120083608 | PROCESS FOR THE PREPARATION OF [4-(2-CHLORO-4- METHOXY-5-METHYLPHENYL)-5-METHYL-THIAZOLO-2-YL]-[2-CYCLOPROPYL-1-(3-FLUOR- O-4-METHYLPHENYL)-ETHYL]-AMINE - The present invention is a process for the preparation of [4-(2-chloro-4-methoxy-5-methylphenyl)-5-methyl-thiazolo-2-yl]-[2-cyclopropyl-1-(3-fluoro-4-methylphenyl)-ethyl]-amine as set forth in formula (I) | 04-05-2012 |
| 20150065725 | ELECTROLUMINESCENT DEVICE USING AZOMETHINE-LITHIUM-COMPLEX AS ELECTRON INJECTION LAYER - In OLEDs, improved efficiency is obtained by compounds which can form inter alia electron injection layers of the formula (I) | 03-05-2015 |
| 548194000 | The chalcogen, X, is in a -C(=X)- group | 10 |
| 20090203918 | METHOD FOR PRODUCING ENANTIOMERIC FORM OF 2,3-DIAMINOPROPIONIC ACID DERIVATIVES - The invention relates to a method for producing enantiomers form of 2,3-diaminopropionic acid derivatives of formula (I) by asymmetric hydrogenation from compounds of formula (II). | 08-13-2009 |
| 20140275554 | CRYSTALLINE FORM OF A SUBSTITUTED THIAZOLYLACETIC ACID TRIETHYLAMINE SALT - The invention relates to a crystalline form of a triethylamine salt of (2Z)-2-(2-amino-5-chlorothiazol-4-yl)-2-(3-N-tert-butoxycarbonylaminopropoxyimino)acetic acid. The invention also relates to processes and intermediates for preparing the crystalline form. The crystalline form is useful as an intermediate for preparing cross-linked glycopeptide-cephalosporin antibiotics. | 09-18-2014 |
| 20160024035 | COMPOSITIONS AND METHODS RELATING TO HEAT SHOCK TRANSCRIPTION FACTOR ACTIVATING COMPOUNDS AND TARGETS THEREOF - The present invention relates to HSF activating compounds, methods for their discovery, and their research and therapeutic uses, as well as pharmaceutically acceptable salts, solvates, chelates, non-covalent complexes, prodrugs, mixtures (including both R and S enantiomeric forms and racemic mixtures thereof), and pharmaceutical Formulations thereof. In particular, the present invention provides compounds capable of facilitating HSF1 homotrimerization, and methods of using such compounds as therapeutic agents to treat a number of conditions associated with irregular HSF1 activity. | 01-28-2016 |
| 548195000 | The -C(=X)- group is bonded directly to the nitrogen | 7 |
| 20080207912 | Method for manufacture of ceftiofur - A process for preparation of ceftiofur of formula (I) of high purity and substantially free from impurities is disclosed. The process comprises reacting [2-(2-aminothiazol-4-yl)]-2-syn-methoxyimino acetic acid-2-benzothiazolyl thioester of formula (II), with 7-amino-3-(2-furanylcarbonylthiomethyl)-3-cephem-4-carboxylic acid of formula (III) in the presence of a mixture of an water-immescible inert organic solvent and water and in the presence of a organic base and isolating ceftiofur of formula (1) substantially free of impurities by, d) adding water to the reaction mixture and selectively partitioning the impurities in the organic phase and ceftiofur (I) in the form of a salt with the base in the aqueous phase, e) acidifying the aqueous phase containing ceftiofur (I) in the form of a salt with the base in the presence of a mixture containing a water-miscible and a water-immiscible organic solvent and in the presence of a saturated aqueous solution of an alkali or alkaline earth containing salt, to partition ceftiofur (I) in the organic phase, and f) isolating ceftiofur (I) of high purity and substantially free of impurities by evaporation of the organic solvent or precipitation by addition of a co-solvent. | 08-28-2008 |
| 20120253048 | RIBONUCLEOTIDE REDUCTASE INHIBITORS AND METHODS OF USE - Provided herein are novel compounds that inhibit ribonucleotide reductase (RR) by binding to RRM2 and interfering with the activity of the RRM1/RRM2 holoenzyme, as well as methods of synthesizing these novel compounds. The compounds may be used to inhibit RR activity and to treat various conditions associated with RRM2 expression, such as for example certain cancer types, mitochondrial diseases, or degenerative diseases. | 10-04-2012 |
| 20130217885 | PHARMACEUTICAL COMPOSITION CONTAINING OPTICALLY ACTIVE COMPOUND HAVING THROMBOPOIETIN RECEPTOR AGONIST ACTIVITY, AND INTERMEDIATE THEREFOR - An optically active 4-phenylthiazole derivative having a thrombopoietin receptor agonist activity and a pharmaceutical composition containing the present compound as an active ingredient are created, and a platelet production regulating agent which can be orally administered is provided. | 08-22-2013 |
| 20140058112 | METHOD FOR PRODUCING AMINOTHIAZOLE DERIVATIVE AND PRODUCTION INTERMEDIATE - Provided is a method for selectively demethylating a 2-methoxy group. Specifically provided is a production method of a compound represented by formula (7) below through the following reactions. | 02-27-2014 |
| 20140121381 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR - The present invention relates to modulators of cystic fibrosis Transmembrane Conductance Regulator (“CFTR”), compositions thereof, and methods therewith. The present invention also relates to methods of treating CFTR mediated diseases using such modulators. | 05-01-2014 |
| 20150087844 | RIBONUCLEOTIDE REDUCTASE INHIBITORS AND METHODS OF USE - Provided herein are novel compounds that inhibit ribonucleotide reductase (RR) by binding to RRM2 and interfering with the activity of the RRM1/RRM2 holoenzyme, as well as methods of synthesizing these novel compounds. The compounds may be used to inhibit RR activity and to treat various conditions associated with RRM2 expression, such as for example certain cancer types, mitochondrial diseases, or degenerative diseases. | 03-26-2015 |
| 20160122308 | RIBONUCLEOTIDE REDUCTASE INHIBITORS AND METHODS OF USE - Provided herein are novel compounds that inhibit ribonucleotide reductase (RR) by binding to RRM2 and interfering with the activity of the RRM1/RRM2 holoenzyme, as well as methods of synthesizing these novel compounds. The compounds may be used to inhibit RR activity and to treat various conditions associated with RRM2 expression, such as for example certain cancer types, mitochondrial diseases, or degenerative diseases. | 05-05-2016 |
| 548198000 | Nitrogen attached indirectly to the thiazole ring by nonionic bonding | 1 |
| 20100190995 | PROCESS FOR PREPARING CYANIMINO-1,3-THIAZOLIDINES - The present invention relates to a process for preparing cyanimino-1,3-thiazolidines, which are important building blocks for the preparation of crop protection active ingredients and pharmaceuticals, by the following scheme: | 07-29-2010 |
